Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,138.80
(
-0.49%
)
US TECH 100
26,370.00
(
-0.75%
)
Dow Jones
49,141.93
(
-0.34%
)
Brent Oil
104.01
(
-0.39%
)
Bitcoin
76,957.92
(
0.80%
)
News Focus
News Focus
Post# of 257458
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122898
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 250595

Thursday, 02/22/2024 11:05:03 AM

Thursday, February 22, 2024 11:05:03 AM

Post# of 257458
MRNA 4Q23 results—2024 outlook:

PR:
https://s29.q4cdn.com/435878511/files/doc_earnings/2023/q4/earnings-result/Q4-23-PR_Final.pdf

CC slides:
https://s29.q4cdn.com/435878511/files/doc_earnings/2023/q4/presentation/Moderna-4Q23-Earnings-Presentation-Final.pdf

MRNA reiterated 2024 guidance for: $4B of product sales (mostly COVID Spikevax, but including some contribution from mRNA-1345 RSV vaccine, which has a 5/12/24 PDUFA date and a planned ACIP panel in late June); and $4.5B in R&D expenses.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up